Press Release

View printer-friendly version << Back

Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA

SEATTLE--(BUSINESS WIRE)--Apr. 20, 2022-- Omeros Corporation (Nasdaq: OMER) today announced the online publication of a manuscript detailing the results of its pivotal study assessing efficacy and safety of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), an often-lethal complication of stem-cell transplantation for which there is no approved treatment. The manuscript – Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation–Associated Thrombotic Microangiopathy – will be published in an upcoming volume of the Journal of Clinical Oncology (JCO) and yesterday was made available online by JCO, the flagship publication of the American Society of Clinical Oncology.

About Omeros Corporation

Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic diseases, including complement-mediated diseases and cancers related to dysfunction of the immune system, as well as addictive and compulsive disorders. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. OMS906, Omeros’ inhibitor of MASP-3, the key activator of the alternative pathway of complement, is initiating a Phase 1b clinical program in paroxysmal nocturnal hemoglobinuria (PNH). In addition to its complement franchise, Omeros has ongoing cutting-edge programs in addiction treatments, immuno-oncology therapeutics and human CAR-T and adoptive T cell therapy systems. More information about Omeros and its programs is available at and in Omeros’ annual, quarterly and current reports filed with the U.S. Securities and Exchange Commission (SEC), which can be accessed at under “Investors & News — Financial Information — SEC Filings” and on the SEC’s website at

Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor and Media Relations

Source: Omeros Corporation